Week in Review: Shanghai Henlius to File for Hong Kong IPO at Valuation of Over $1 Billion

Deals and Financings   Fosun Pharma plans a Hong Kong IPO for Shanghai Henlius Biotech, its antibody JV subsidiary devoted to novel biotech and biosimilar candidates; GO Therapeutics of Boston signed a $195 million licensing deal with Roche to develop cancer antibodies; last year, Shenzhen Salubris acquired China rights to GO products in return for a $5 million investment; Aohua Endoscopy, a Shanghai endoscopy device maker, raised $44 million in a D round led by Lyfe Capital, a Shanghai healthcare-focused PE firm; HiFiBiO Therapeutics, a US-France-China biopharma, will collaborate with Kite Pharma to discover neoantigen-reactive T cell receptors for cancer; Cellular Biomedicine was granted a license for a next-gen neoantigen-reactive tumor infiltrating lymphocyte technology from the US NIH; Ping An Good Doctor will partner with CR Sanjiu, combining the internet platform with CR Sanjiu's portfolio of OTC and prescription TCM products; Company News   PharmaBlock Sciences of Nanjing, a CDMO, has acquired a GMP compliant manufacturing facility in China from Porton Pharma; Trials and Approvals   CANbridge Pharma of Beijing filed a China NDA for Nerlynx®, which could become the third foreign drug approved in China without a clinical trial; Innovent Biologics of Suzhou reported its anti-CD47 mAb has been approved to start US clinical trials in patients with advanced malignancies and lymphomas. Stock Symbols: (HK: 02196: SHA: 600196) (SWX: ROG) (SHZ: 2294) (NSDQ: CBMG) (HK: 1833) (SZE: 300725) (SZE: 300363) Share this with colleagues: // //